“These results further support the value of secukinumab in improving the heterogeneous psoriatic arthritis disease spectrum, including health-related quality of life measures, in both TNFi-naïve and TNFi-inadequate responder patients,”...
“These results further support the value of secukinumab in improving the heterogeneous psoriatic arthritis disease spectrum, including health-related quality of life measures, in both TNFi-naïve and TNFi-inadequate responder patients,”...
“These results further support...